1. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.
3. Bouattour M, Mehta N, He AR, Cohen EI, Nault JC. Systemic treatment for advanced hepatocellular carcinoma. Liver Cancer. 2019;8(5):341–58..
4. Rimassa L, Pressiani T, Merle P. Systemic treatment options in hepatocellular carcinoma. Liver cancer. 2019;8(6):427–46.
5. Raoul JL, Adhoute X, Penaranda G, Perrier H, Castellani P, Oules V, et al. Sorafenib: experience and better manage-ment of side effects improve overall survival in hepatocellular carcinoma patients: a real-life retrospective analysis. Liver Cancer. 2019;8(6):457–67..